Clinical trials in Alzheimer's disease frequently include the measurement of risk genes (i.e., the APOE e4 allele), and advancements in direct-to-consumer genetic testing (e.g., 23andMe) have made these biological data widely available to the public. Is it helpful or harmful for clinicians to disclose information on genetic risk for Alzheimer's disease to patients and research participants? How can we explain concepts such as risk and incomplete penetrance to our patients? We pose these questions, and others, to a neuropsychologist with research and clinical experience in this arena, as well as provide a primer on genetics. Show notes are available at www.NavNeuro.com/13 _________________ If you'd like to support the show, here are a few easy ways: 1) Get APA-approved CE credits for listening to select episodes: www.NavNeuro.com/INS 2) Tell your friends and colleagues about it 3) Subscribe (free) and leave an Apple Podcasts rating/review: www.NavNeuro.com/itunes 4) Check out our book Becoming a Neuropsychologist, and leave it an Amazon rating Thanks for listening, and join us next time as we continue to navigate the brain and behavior! [Note: This podcast and all linked content is intended for general educational purposes only and does not constitute the practice of psychology or any other professional healthcare advice and services. No professional relationship is formed between hosts and listeners. All content is to be used at listeners' own risk. Users should always seek appropriate medical and psychological care from their licensed healthcare provider.]

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related